SEGMENTS (Tables)

9 Months Ended

Sep. 30, 2022

Segment Reporting [Abstract]

SCHEDULE OF SEGMENT INFORMATION

The following table summarizes the Company’s segment information for the following balance sheet dates presented, and for the nine months ended September 30, 2022 and 2021:

	Real Estate			Digital Transformation Technology			Biohealth Business			Other			Total
Nine Months Ended on September 30, 2022
Revenue	$	2,494,707		$	14,066		$	771,847		$	319,862		$	3,600,482
Cost of Sales		(1,880,914	)		(4,574	)		(512,931	)		(80,177	)		(2,478,596	)
Gross Margin		613,793			9,492			258,916			239,685			1,121,886
Operating Expenses		(1,988,323	)		(255,764	)		(587,051	)		(3,669,563	)		(6,500,701	)
Operating Loss		(1,374,530	)		(246,272	)		(328,135	)		(3,429,878	)		(5,378,815	)
Other Income (Expense)		26,505			(1,359,913	)		(3,535,998	)		(20,677,529	)		(25,546,935	)
Net Loss Before Income Tax		(1,348,025	)		(1,606,185	)		(3,864,133	)		(24,107,407	)		(30,925,750	)

	Real Estate			Digital Transformation Technology			Biohealth Business			Other			Total
Nine Months Ended on September 30, 2021
Revenue	$	12,026,069		$	-		$	4,919,844		$	-		$	16,945,913
Cost of Sales		(8,291,698	)		-			(218,507	)		-			(8,510,205	)
Gross Margin		3,734,371			-			4,701,337			-			8,435,708
Operating Expenses		(901,236	)		(173,594	)		(3,451,152	)		(8,940,432	)		(13,466,414	)
Operating (Loss) Income		2,833,135			(173,594	)		1,250,185			(8,940,432	)		(5,030,706	)
Other Expense		(9,063	)		403,000			(33,960,503	)		(53,727,340	)		(87,293,906	)
Net Loss Before Income Tax		2,824,072			229,406			(32,710,318	)		(62,667,772	)		(92,324,612	)
September 30, 2022
Cash and Restricted Cash	$	2,678,530		$	389,118		$	1,698,868		$	18,469,310		$	23,235,826
Total Assets		49,820,288			1,273,132			6,074,039			107,497,047			164,664,506
December 31, 2021
Cash and Restricted Cash	$	7,493,921		$	245,780		$	2,629,464		$	50,433,014		$	60,802,179
Total Assets		55,465,600			2,199,466			11,056,779			115,488,298			184,210,143